@article{0a7d9765a626408097bd6d95a5cc5e71,
title = "Experimental Pain and Auditory Sensitivity in Overactive Bladder Syndrome: A Symptoms of the Lower Urinary Tract Dysfunction Research Network (LURN) Study",
abstract = "Purpose:The objective of this study was to investigate the presence of nonbladder sensory abnormalities in participants with overactive bladder syndrome (OAB).Materials and Methods:Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) study participants with OAB symptoms and controls were recruited from 6 U.S. tertiary referral centers. Quantitative sensory testing (QST) was performed to determine pressure pain sensitivity at the thumbnail bed and auditory sensitivity. Fixed and mixed effect multivariable linear regressions and Weibull models were used to compare QST responses between groups. Pearson correlations were used to assess the relationship between QST measures. Associations between QST and self-reported symptoms were explored with linear regression.Results:A total of 297 participants were analyzed (191 OAB, 106 controls; 76% white, 51% male). OAB cases were older than controls (57.4 vs 52.2 years, p=0.015). No significant differences in experimental thumbnail (nonbladder) pain or auditory sensitivity were detected between OAB cases and controls. Correlations between pressure and auditory derived metrics were weak to moderate overall for both groups, with some significantly stronger correlations for cases. Exploratory analyses indicated increased pressure pain and auditory sensitivity were modestly associated with greater self-reported bladder pain and pain interference with physical function.Conclusions:As a group, no significant differences between OAB cases and controls were observed in experimental nonbladder pain or auditory sensitivity during QST. Associations between QST outcomes and clinical pain raise the possibility of centrally mediated sensory amplification in some individuals with OAB.",
keywords = "auditory perception, central nervous system sensitization, pain perception, pain threshold, pain measurement",
author = "Harte, {Steven E.} and Jon Wiseman and Ying Wang and Smith, {Abigail R.} and Yang, {Claire C.} and Margaret Helmuth and Karl Kreder and Kruger, {Grant H.} and Gillespie, {Brenda W.} and Cindy Amundsen and Ziya Kirkali and Lai, {H. Henry}",
note = "Funding Information: This is publication number 27 of the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN). This study is supported by the National Institute of Diabetes & Digestive & Kidney Diseases through cooperative agreements (grants DK097780, DK097772, DK097779, DK099932, DK100011, DK100017, DK099879). Research reported in this publication was supported at Northwestern University, in part, by the National Institutes of Health's National Center for Advancing Translational Sciences, Grant Number UL1TR001422. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The following individuals were instrumental in the planning and conduct of this study at each of the participating institutions: Duke University, Durham, North Carolina (DK097780): PIs: Cindy Amundsen, MD, Eric Jelovsek, MD; Co-Is: Kathryn Flynn, PhD, Matthew O. Fraser, PhD, Todd Harshbarger, PhD, Jim Hokanson, PhD, Aaron Lentz, MD, Michelle O{\textquoteright}Shea, MD, David Page, PhD, Nazema Siddiqui, MD, Kevin Weinfurt, PhD Lisa Wruck, PhD; Study Coordinators: Yasmeen Bruton, Paige Green, Folayan Morehead. University of Iowa, Iowa City, Iowa (DK097772): PIs: Catherine S Bradley, MD, Karl Kreder, MD, MBA, MSCE; Co-Is: Bradley A. Erickson, MD, MS, Daniel Fick, MD, Vince Magnotta, PhD, Philip Polgreen, MD, MPH; Study Coordinators: Mary Eno, Sarah Heady, Chelsea Poesch. Northwestern University, Chicago, Illinois (DK097779): PIs: James W Griffith, PhD, Kimberly Kenton, MD, MS, Brian Helfand, MD, PhD; Co-Is: Carol Bretschneider, MD, David Cella, PhD, Sarah Collins, MD, Julia Geynisman-Tan, MD, Alex Glaser, MD, Christina Lewicky-Gaupp, MD, Margaret Mueller, MD; Study Coordinators: Sylwia Clarke, Melissa Marquez, Pooja Sharma, Michelle Taddeo, Pooja Talaty. Dr. Helfand and Ms. Talaty are at NorthShore University HealthSystem. University of Michigan Health System, Ann Arbor, Michigan (DK099932): PI: J Quentin Clemens, MD, FACS, MSCI; Co-Is: John DeLancey, MD, Dee Fenner, MD, Rick Harris, MD, Steve Harte, PhD, Anne P. Cameron, MD, Aruna Sarma, PhD, Giulia Lane, MD; Study Coordinators: Ashly Chimner, Linda Drnek, Emma Keer, Marissa Moore, Greg Mowatt, Sarah Richardson. University of Washington, Seattle, Washington (DK100011): PI: Claire Yang, MD; Co-I: Anna Kirby, MD; Study Coordinators: Lois Meryman, Brenda Vicars, RN. Washington University in St. Louis, St. Louis, Missouri (DK100017): PI: H. Henry Lai, MD; Co-Is: Gerald L. Andriole, MD, Joshua Shimony, MD, PhD; Study Coordinators: Linda Black, Vivien Gardner, Patricia Hayden, Aleksandra Klim, RN, MHS, CCRC. Arbor Research Collaborative for Health, Data Coordinating Center (DK099879): PI: Robert Merion, MD, FACS; Co-Is: Victor Andreev, PhD, DSc, Brenda Gillespie, PhD, Abigail Smith, PhD; Project Manager: Melissa Fava, MPA, PMP; Clinical Monitor: Melissa Sexton, BA, CCRP; Research Analysts: Margaret Helmuth, MA, Jon Wiseman, MS, Jane Liu, MPH; Project Associate: Levi Hurley. National Institute of Diabetes and Digestive and Kidney Diseases, Division of Kidney, Urology, and Hematology, Bethesda, Maryland: Project Scientist: Ziya Kirkali, MD; Project Officer: Christopher Mullins, PhD; Project Advisor: Julie Barthold, MD. Funding Information: Conflicts of Interest: S.E.H. received funding from the National Institutes of Health (NIH) for and outside the present work. He is co-inventor of the MAST device (U.S. patent # 9307906) used in this study and a member of Arbor Medical Innovations, LLC, its licensee from the University of Michigan. He is also consultant for Aptinyx, Eli Lilly, atai Life Sciences, and Heron Therapeutics, and has received research funding from Aptinyx and Arbor Medical Innovations. C.L.A. received research funding from NIH and BlueWind Medical Ltd. G.H.K. has received funding from the NIH; a co-inventor of the MAST system, and founder of Arbor Medical Innovations. H.H.L. received funding from the NIH. He is also a consultant or clinical investigator for Medtronic, Allergan, Neuspera, Teva, and IronWood pharmaceuticals. Y.W. was supported by an NIH K99 award (Grant # 5K99AT010012) and Indiana University Health–Indiana University School of Medicine Strategic Research Initiative. Publisher Copyright: {\textcopyright} 2022 Lippincott Williams and Wilkins. All rights reserved.",
year = "2022",
month = jan,
day = "1",
doi = "10.1097/JU.0000000000002147",
language = "English",
volume = "207",
pages = "161--171",
journal = "Journal of Urology",
issn = "0022-5347",
number = "1",
}